# Optimizing H. Pylori Eradication Regimen Under Intensified Acid Suppression

> **NCT07750938** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 316 (estimated)

## Conditions studied

- HELICOBACTER PYLORI INFECTIONS

## Interventions

- **DRUG:** Keverprazan Hydrochloride 20 mg TID
- **DRUG:** Minocycline 100 mg (10-Day Regimen)
- **DRUG:** Keverprazan Hydrochloride 20 mg BID
- **DRUG:** Bismuth Potassium Citrate 240 mg
- **DRUG:** Amoxicillin 1000 mg
- **DRUG:** Minocycline 100 mg (14-Day Regimen)

## Key facts

- **NCT ID:** NCT07750938
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-07-10
- **Final completion:** 2028-08-10
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750938, "Optimizing H. Pylori Eradication Regimen Under Intensified Acid Suppression". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07750938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*